生物技术公司Allogene Therapeutics Inc(通称"ALLO")今日股价盘中大跌5.33%,引发市场广泛关注。公司最新公布的2024年第三季度财报显示,公司在业绩和收入方面均未能达到分析师预期,这被认为是导致股价下跌的主要原因。
具体来看,Allogene Therapeutics Inc本季度调整后每股亏损达32美分,高于分析师预期的33美分亏损。同时公司在本财季零收入,也未能达到分析师对1293万美元收入的预期。这意味着,公司目前仍未能真正开始商业化运营并实现盈利。
分析人士认为,近期连续的业绩不佳加上收入预期的失利,令投资者对Allogene Therapeutics Inc的发展前景失去信心,从而引发了当日盘中股价的大幅下跌。不过,就目前市场普遍看好该公司的长期前景,大多数分析师仍对其维持"买入"评级。该公司能否及时扭转业绩下滑并实现预期,仍需进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.